RefleXion Medical, Inc., a biotargeting oncology company developing the first and only biology-guided radiotherapy (BgRT) machine* for targeted cancer treatment has received a $60M senior secured term loan from Oxford Finance LLC. The company plans to use the loan to support the completion of the FDA clearance process for its biology-guided BgRT system and its subsequent commercial launch.
Building from Positron
Emission Tomography
Positron emission tomography (PET) is an established
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Amgen, Syapse Partner to Develop Observational Research Analytics for Precision Oncology
Amgen, a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, today announced a precision medicine collaboration in oncology. Under the terms of the collaboration, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology.Generates Insights from Real-World Evidence for Potential Use in Regulatory FilingsThis effort will identify existing patients within
Read More
7 Trends Accelerating “TechBio” – The Life Sciences and Computer Sciences Convergence
We are now living in what I’m calling the
TechBio revolution. That’s not a typo that should read BioTech, but rather a
new way of looking at the convergence of technology and biology.
TechBio is defined as an engineering-first approach of biological processes for industrial, and other purposes, especially the genetic manipulation of microorganisms for the production of antibiotics, hormones, and so on. A process that uses AI and data-enabled discovery to complement the exploration of
Read More
Accenture: How New Science is Reshaping The Biopharma Landscape
Accenture has released new research that unveils strong evidence that the biopharma industry is facing compressive disruption when a series of innovations, macroeconomic factors, and other changes combine to squeeze profits over a decade or more. However, it also unveils a powerful growth engine: an emerging category that Accenture calls 'New Science' that is expected to drive 54% of the biopharma industry’s growth through 2022.
What is New Science?
New Science is an evolving, unique
Read More
PAREXEL Unveils Patient Sensor Solution To Transform Clinical Trial Data Collection
PAREXEL International Corporation (NASDAQ: PRXL), a biopharmaceutical services provider has unveiled its new patient sensor solution that securely captures, transmits, stores and visualizes study subject data in clinical trials. The new offering is powered by he Perceptive MyTrials® Analytics platform, enables an end-to-end services and technology solution that facilitates the remote collection of study subject data via medical devices.The PAREXEL® patient sensor solution supports the generation
Read More
Pharma Deals Vital to Offsetting $2.5B Drug Development Cost
With the average cost of getting a novel drug to market at almost $2.5 billion, and few products achieving blockbuster status, deal-making is becoming increasingly vital for pharmaceutical companies to offset rising Research and Development (R&D) costs, says business intelligence provider GBI Research.
The company’s latest CBR Pharma report* states that pharmaceutical companies are considering various strategies to overcome the current challenges, which also include shifts in patent laws
Read More
BioMaryland Center Awards $1.5M to Johns Hopkins and 7 Biotech Companies
Governor Martin O’Malley announced today that the State, through the BioMaryland Center, has awarded nearly $1.5 million to seven innovative life sciences companies and one educational institution through its Biotechnology Development Awards program. The companies, which received up to $200,000 each, will use the funding to accelerate the commercialization of a wide range of treatments and technologies; including a device that detects concussions in youths engaged in sports; a tool that takes a
Read More
